COMPANY

Glycologix

HQ: Beverly, MA source · glycologix.com ↗ · New England

Keywords: interstitial cystitis bladder pain syndrome osteoarthritis

Location: Beverly, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

NIH awards 3

Annual award amounts. Total $2.3M.

Jul 1, 2021 NIH award 5R44DK116356-03 FY2021: $1,266,580 awarded for that fiscal year; activity R44 (SBIR); PI HURST, ROBERT EVAN; recipient as written: GLYCOLOGIX, LLC, BEVERLY, MA. SuperGAGs for Intravesicular Treatment of Int source ↗
Jun 29, 2020 NIH award 2R44DK116356-02 FY2020: $730,062 awarded for that fiscal year; activity R44 (SBIR); PI HURST, ROBERT EVAN; recipient as written: GLYCOLOGIX, LLC, BEVERLY, MA. SuperGAGs for Intravesicular Treatment of Inter source ↗
May 25, 2018 NIH award 1R43DK116356-01A1 FY2018: $287,615 awarded for that fiscal year; activity R43 (SBIR); PI HURST, ROBERT EVAN; recipient as written: GLYCOLOGIX, LLC, BEVERLY, MA. SuperGAGs for Intravesicular Treatment of Int source ↗

SEC Form D raise Raised $800K (Form D filed Dec 29, 2025). SEC Form D 0001903671-25-000002 (Dec 29, 2025)
Evidence (1 event)
- Dec 29, 2025 · SEC Form D 0001903671-25-000002
  Name of Issuer: Glycologix, Inc.; CIK: 1903671; Address: Beverly, MA; Submission type: D; Filing date: 2025-12-29; Industry Group: Other Technology; Date of First Sale: 2025-12-12; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 800000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals